Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer

About this update from Cascade Copper Corp.

[{"type":"text","content":"\n\n\n\nBELLEVUE, WA, June 11 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY)\n(the "Company") today announced that the first patient has been treated in a\nPhase 1b clinical trial of PX-12 in patients with advanced metastatic cancer.\nPX-12 is a proprietary small molecule inhibitor of thioredoxin, a protein that\nregulates diverse molecular pathways that contribute to the growth, survival\nand drug resistance of many cancers.\n\n\nThe primary objective of the Phase 1b dose-escalation trial is to\ndetermine the safety and tolerability of a 72-hour continuous infusion of\nPX-12 given on the first three days of a 21-day cycle. Other objectives of the\ntrial include an evaluation of the pharmacokinetics and pharmacodynamics of\nthe prolonged infusion, together with identification of any anti-tumor\nactivity. The trial is expected to enroll up to 28 patients at three centers\nin the United States.\n\n\nAbout PX-12\n\n\nPX-12 is a small molecule designed to inhibit thioredoxin-1. Increased\nlevels of thioredoxin-1 have been noted in many types of cancer cells,\nincluding hepatoma, lung cancers, squamous cervical carcinoma, primary gastric\ncancers and colorectal carcinomas. Increased levels of thioredoxin-1 are\nassociated with decreased sensitivity to a variety of common chemotherapy\nagents and may cause or contribute to drug resistance.\n\n\nAn initial Phase 1 trial of PX-12 in 38 patients with advanced metastatic\ncancer showed that PX-12 was well tolerated and produced a decrease in plasma\nconcentrations of thioredoxin that was significantly correlated with increased\npatient survival. Fifteen of the 38 patients achieved stable disease of up to\n322 days. Oncothyreon is also currently conducting a Phase 2 trial of PX-12\ngiven as a 3-hour infusion daily for five days of a 21-day cycle in patients\nwith advanced pancreatic cancer who have progressed on gemcitabine or a\ngemcitabine-containing regimen.\n\n\nAbout Oncothyreon\n\n\nOncothyreon is a biotechnology company specializing in the development of\ninnovative therapeutic products for the treatment of cancer. Oncothyreon's\ngoal is to develop and commercialize novel synthetic vaccines and targeted\nsmall molecules that have the potential to improve the lives and outcomes of\ncancer patients. For more information, visit www.oncothyreon.com.\n\n\nForward-Looking St...

More updates from Cascade Copper Corp.